EFSD/Novo Nordisk Partnership for Diabetes Research in Europe (
<<< Προηγούμενη σελίδα
Euro 3 million to support European diabetes research
The European Foundation for the Study of Diabetes (EFSD), the research Foundation of EASD, and Novo Nordisk are pleased to announce their support of diabetes research with the contribution of Euro 3 million over the next three years. "The Programme, which will be governed by the EFSD, will support European research into understanding the cause and treatment of all forms of diabetes," explains Dr. Viktor Jorgens, Executive Director of EFSD.
Applications will be welcomed from all non-profit institutions in Europe within any area of basic or clinical diabetes research. The Programme Announcement will be published in the official journal of EASD, Diabetologia, in January 2010 and on the EFSD website.
"Diabetes prevalence is growing rapidly. There is, therefore, an urgent need to understand the molecular mechanisms behind this disease and its associated co-morbidities," says Peter Kurtzhals, Senior Vice President and Head of Diabetes Research at Novo Nordisk. "We hope that this grant will support research that otherwise may not be possible, and that our improved knowledge will help guide the development of safe and effective therapies in the future."
The deadline for submission of applications is 01 April 2010. Application forms may be requested from: email@example.com,
In 1999, the European Association for the Study of Diabetes (EASD) increased its commitment to stimulate diabetes research in Europe by creating the European Foundation for the Study of Diabetes (EFSD). Since its inception, EFSD has committed over Euro 62 million to diabetes research in Europe by various funding means. In the last five years, the Foundation has become a significant European funding agency for diabetes research, and is continually striving to enhance awareness in Europe of the severity and magnitude of this devastating disease.
About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 29,000 employees in 81 countries, and markets its products in 179 countries. For more information, visit novonordisk.com